{"transactions":[{"id":1413602,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-09-05T20:24:30.000Z","date":"2024-09-04","kind":"sale","planned":false,"acquired":false,"shares":7050,"price":0.7218,"value":5088.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":391054,"source":{"system":"sec-edgar","filing":"0000950170-24-104031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024104031/ownership.xml","form_type":"4"}},{"id":1488112,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-06-06T20:03:43.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":652,"price":0.99,"value":645.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":398104,"source":{"system":"sec-edgar","filing":"0000950170-24-069860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024069860/ownership.xml","form_type":"4"}},{"id":1602504,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common","published_at":"2024-03-05T00:39:44.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":6162,"price":1.2,"value":7394.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":398756,"source":{"system":"sec-edgar","filing":"0000950170-24-025191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024025191/ownership.xml","form_type":"4"}},{"id":1602503,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common","published_at":"2024-03-05T00:39:44.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":27687,"price":1.17,"value":32393.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":404918,"source":{"system":"sec-edgar","filing":"0000950170-24-025191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024025191/ownership.xml","form_type":"4"}},{"id":1609566,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-02-29T22:35:54.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":188205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the award of RSUs pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025."}],"balance_after":432605,"source":{"system":"sec-edgar","filing":"0000950170-24-023292","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024023292/ownership.xml","form_type":"4"}},{"id":1609565,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-02-29T22:35:54.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":2545,"price":1.3238,"value":3369.071,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units (\"RSUs\"). The sale does not represent a discretionary trade by the reporting person."}],"balance_after":244400,"source":{"system":"sec-edgar","filing":"0000950170-24-023292","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024023292/ownership.xml","form_type":"4"}},{"id":1653118,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-02-08T21:36:16.000Z","date":"2024-02-06","kind":"sale","planned":false,"acquired":false,"shares":4205,"price":1.5865,"value":6671.2325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":246945,"source":{"system":"sec-edgar","filing":"0000950170-24-012832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024012832/ownership.xml","form_type":"4"}},{"id":1670700,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-01-25T23:47:58.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units (\"PSUs\") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date."}],"balance_after":251150,"source":{"system":"sec-edgar","filing":"0000950170-24-007588","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000095017024007588/ownership.xml","form_type":"4"}},{"id":1788822,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-09-05T20:30:00.000Z","date":"2023-09-01","kind":"sale","planned":false,"acquired":false,"shares":6913,"price":1.3313,"value":9203.2769,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units.  The sale does not represent a discretionary trade by the reporting person."}],"balance_after":237817,"source":{"system":"sec-edgar","filing":"0001209191-23-048162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919123048162/doc4.xml","form_type":"4"}},{"id":1866367,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-06-05T20:10:17.000Z","date":"2023-06-02","kind":"sale","planned":true,"acquired":false,"shares":631,"price":2.22,"value":1400.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":244730,"source":{"system":"sec-edgar","filing":"0001209191-23-034262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919123034262/doc4.xml","form_type":"4"}},{"id":1978793,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-03-02T22:30:12.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":11205,"price":3.0292,"value":33942.186,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."}],"balance_after":245361,"source":{"system":"sec-edgar","filing":"0001209191-23-014843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919123014843/doc4.xml","form_type":"4"}},{"id":1978792,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-03-02T22:30:12.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024."}],"balance_after":256566,"source":{"system":"sec-edgar","filing":"0001209191-23-014843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919123014843/doc4.xml","form_type":"4"}},{"id":1983126,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-03-01T21:05:35.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":2802,"price":3.0368,"value":8509.1136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."}],"balance_after":161566,"source":{"system":"sec-edgar","filing":"0001209191-23-014078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919123014078/doc4.xml","form_type":"4"}},{"id":2026237,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-02-08T21:11:19.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":4141,"price":3.4,"value":14079.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."}],"balance_after":164368,"source":{"system":"sec-edgar","filing":"0001209191-23-007775","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919123007775/doc4.xml","form_type":"4"}},{"id":2168794,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2022-09-02T00:59:41.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on August 31, 2022 pursuant to the Plan.  The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024."}],"balance_after":45000,"derivative":{"exercise_price":5.06,"expiration_date":"2032-08-30","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-22-048394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919122048394/doc4.xml","form_type":"4"}},{"id":2168793,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2022-09-02T00:59:41.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the \"Plan\").  RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.  The RSUs vest  as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024."}],"balance_after":168509,"source":{"system":"sec-edgar","filing":"0001209191-22-048394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919122048394/doc4.xml","form_type":"4"}},{"id":2241469,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO, Treasurer"}}],"security":"Common Stock","published_at":"2022-06-06T21:40:21.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":3,"price":6.067,"value":18.201,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."}],"balance_after":138509,"source":{"system":"sec-edgar","filing":"0000899243-22-021234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000089924322021234/doc4.xml","form_type":"4"}},{"id":2241468,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO, Treasurer"}}],"security":"Common Stock","published_at":"2022-06-06T21:40:21.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":598,"price":6.04,"value":3611.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."}],"balance_after":138512,"source":{"system":"sec-edgar","filing":"0000899243-22-021234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000089924322021234/doc4.xml","form_type":"4"}},{"id":2359668,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-02T20:33:36.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":111600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 28, 2022 pursuant to the Plan.  The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":111600,"derivative":{"exercise_price":10.33,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":111600},"source":{"system":"sec-edgar","filing":"0001209191-22-014628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919122014628/doc4.xml","form_type":"4"}},{"id":2359667,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2022-03-02T20:33:36.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":2398,"price":10.2375,"value":24549.525,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price.  These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":139110,"source":{"system":"sec-edgar","filing":"0001209191-22-014628","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919122014628/doc4.xml","form_type":"4"}},{"id":2359666,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2022-03-02T20:33:36.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":88200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the \"Plan\").  RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.  The RSUs vest in four equal annual installments beginning February 28, 2023."}],"balance_after":141508,"source":{"system":"sec-edgar","filing":"0001209191-22-014628","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919122014628/doc4.xml","form_type":"4"}},{"id":2406009,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2022-02-09T22:25:43.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":3947,"price":9.862,"value":38925.314,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees."}],"balance_after":53308,"source":{"system":"sec-edgar","filing":"0001209191-22-008126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919122008126/doc4.xml","form_type":"4"}},{"id":2688557,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO, Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-01T21:53:29.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 1, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on June 1, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":15000,"derivative":{"exercise_price":9.15,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-021368","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000089924321021368/doc4.xml","form_type":"4"}},{"id":2688556,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO, Treasurer"}}],"security":"Common Stock","published_at":"2021-06-01T21:53:29.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the \"Plan\"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning June 1, 2022."}],"balance_after":57255,"source":{"system":"sec-edgar","filing":"0000899243-21-021368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000089924321021368/doc4.xml","form_type":"4"}},{"id":2825516,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-02T01:16:00.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":59968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 25, 2021 pursuant to the Plan.  The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":59968,"derivative":{"exercise_price":14.56,"expiration_date":"2031-02-24","underlying":"Common Stock","underlying_shares":59968},"source":{"system":"sec-edgar","filing":"0001209191-21-015486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919121015486/doc4.xml","form_type":"4"}},{"id":2825515,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2021-03-02T01:16:00.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":22013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the \"Plan\"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 24,450 RSUs previously reported in Table II, and 5,292 shares of common stock."}],"balance_after":51755,"source":{"system":"sec-edgar","filing":"0001209191-21-015486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919121015486/doc4.xml","form_type":"4"}},{"id":2853592,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2021-02-17T23:46:30.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":2858,"price":15.5191,"value":44353.5878,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees."}],"balance_after":5292,"source":{"system":"sec-edgar","filing":"0001209191-21-011488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919121011488/doc4.xml","form_type":"4"}},{"id":2871308,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Restricted Stock Units","published_at":"2021-02-10T01:32:35.000Z","date":"2021-02-05","kind":"exercise","acquired":false,"shares":8150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 5, 2020, the reporting person was granted 32,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.  25% of the restricted stock units vested on February 5, 2021.  Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 5, 2020, the reporting person was granted 32,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.  25% of the restricted stock units vested on February 5, 2021.  Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date."}],"balance_after":24450,"derivative":{"underlying":"Common Stock","underlying_shares":8150},"source":{"system":"sec-edgar","filing":"0001209191-21-009076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919121009076/doc4.xml","form_type":"4"}},{"id":2871307,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2021-02-10T01:32:35.000Z","date":"2021-02-05","kind":"exercise","acquired":true,"shares":8150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."}],"balance_after":8150,"source":{"system":"sec-edgar","filing":"0001209191-21-009076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919121009076/doc4.xml","form_type":"4"}},{"id":3284074,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Restricted Stock Units","published_at":"2020-02-07T21:18:38.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":32600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date."}],"balance_after":32600,"derivative":{"underlying":"Common Stock","underlying_shares":32600},"source":{"system":"sec-edgar","filing":"0001209191-20-007508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919120007508/doc4.xml","form_type":"4"}},{"id":3284073,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-07T21:18:38.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":87600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 5, 2020.  The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":87600,"derivative":{"exercise_price":18,"expiration_date":"2030-02-04","underlying":"Common Stock","underlying_shares":87600},"source":{"system":"sec-edgar","filing":"0001209191-20-007508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919120007508/doc4.xml","form_type":"4"}},{"id":3635299,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2019-02-25T22:14:21.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 25, 2019.  The shares underlying this option vest as to 25% of the shares on February 25, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":150000,"derivative":{"exercise_price":5.06,"expiration_date":"2029-02-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-013078","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503802/000120919119013078/doc4.xml","form_type":"4"}},{"id":3805659,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2018-09-28T20:55:11.000Z","date":"2018-09-27","kind":"grant","acquired":true,"shares":1387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares\nsubject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":2775,"derivative":{"exercise_price":42.22,"exercise_date":"2018-09-27","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":1387},"source":{"system":"sec-edgar","filing":"0001735276-18-000072","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000072/edgardoc.xml","form_type":"4"}},{"id":3805658,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2018-09-28T20:55:11.000Z","date":"2018-09-27","kind":"grant","acquired":true,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares\nsubject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":5400,"derivative":{"exercise_price":88.95,"exercise_date":"2018-09-27","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001735276-18-000072","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000072/edgardoc.xml","form_type":"4"}},{"id":3834872,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2018-08-23T20:13:27.000Z","date":"2018-08-21","kind":"grant","acquired":true,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee.  Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":3600,"derivative":{"exercise_price":88.95,"exercise_date":"2018-08-21","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001735276-18-000058","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000058/edgardoc.xml","form_type":"4"}},{"id":3844932,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2014 (right to buy)","published_at":"2018-08-14T22:00:06.000Z","date":"2018-08-10","kind":"grant","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award."}],"balance_after":2750,"derivative":{"exercise_price":96.45,"exercise_date":"2018-08-10","expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":3844931,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2013 (right to buy)","published_at":"2018-08-14T22:00:06.000Z","date":"2018-08-10","kind":"grant","acquired":true,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock.  One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award."}],"balance_after":1666,"derivative":{"exercise_price":63,"exercise_date":"2018-08-10","expiration_date":"2023-12-18","underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":3844930,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-14T22:00:06.000Z","date":"2018-07-10","kind":"other","acquired":true,"shares":23,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":276,"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":3844929,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-14T22:00:06.000Z","date":"2018-04-16","kind":"other","acquired":true,"shares":22,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":253,"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":3844928,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-14T22:00:06.000Z","date":"2018-01-17","kind":"other","acquired":true,"shares":5,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":231,"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":3844927,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-14T22:00:06.000Z","date":"2018-08-13","kind":"tax_withholding","acquired":false,"shares":449,"price":90.95,"value":40836.55,"ownership":{"direct":true},"balance_after":563,"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":3844926,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-14T22:00:06.000Z","date":"2018-08-13","kind":"grant","acquired":true,"shares":1012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock.  The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee.  Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested."}],"balance_after":1012,"source":{"system":"sec-edgar","filing":"0001735276-18-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000049/edgardoc.xml","form_type":"4"}},{"id":4015852,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-03-05T22:49:26.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 4,000 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months"}],"balance_after":4000,"derivative":{"exercise_price":119.13,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001553878-18-000013","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000013/edgardoc.xml","form_type":"4"}},{"id":4068737,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-02-09T22:04:45.000Z","date":"2017-09-22","kind":"other","acquired":false,"shares":1950,"price":115.47,"value":225166.5,"ownership":{"direct":false,"nature":"By Managed Account"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person has diversified his retirement plan by selling shares of ALNY common stock in his 401(k) plan received from the ALNY 401(k) matching contribution program."}],"balance_after":226,"source":{"system":"sec-edgar","filing":"0001553878-18-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000001/primary_doc.xml","form_type":"5"}},{"id":4104379,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":0,"derivative":{"exercise_price":97.72,"exercise_date":"2015-12-07","expiration_date":"2025-12-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104378,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":6187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":2063,"derivative":{"exercise_price":96.45,"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":6187},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104377,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":3600,"derivative":{"exercise_price":88.95,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104376,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":3439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":63,"expiration_date":"2023-12-18","underlying":"Common Stock","underlying_shares":3439},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104375,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":1388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":4162,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":1388},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104374,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2014 (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":0,"derivative":{"exercise_price":96.45,"exercise_date":"2017-07-07","expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104373,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2014 (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":2750,"derivative":{"exercise_price":96.45,"exercise_date":"2016-02-01","expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104372,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2013 (right to buy)","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":0,"derivative":{"exercise_price":63,"exercise_date":"2017-09-20","expiration_date":"2023-12-17","underlying":"Common Stock","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104371,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":600,"price":135,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $134.94 to $135.10"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104370,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":400,"price":133.83,"value":53532.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $133.78 to $134.11."}],"balance_after":600,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104369,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":1591,"price":132.98,"value":211571.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $132.75 to $133.71."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104368,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":12405,"price":132.18,"value":1639692.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $131.75 to $132.71."}],"balance_after":2591,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104367,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":16500,"price":131.2,"value":2164800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $130.74 to $131.73."}],"balance_after":14996,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104366,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":5249,"price":130.42,"value":684574.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $129.74 to $130.72."}],"balance_after":31496,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104365,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":3439,"price":63,"value":216657.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":36745,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104364,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":6187,"price":96.45,"value":596736.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":33306,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104363,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":10000,"price":97.72,"value":977200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":27119,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104362,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":2750,"price":96.45,"value":265237.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":17119,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104361,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":2750,"price":96.45,"value":265237.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":14369,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104360,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":3600,"price":88.95,"value":320220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":11619,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104359,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":1667,"price":63,"value":105021.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":8019,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4104358,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-08T22:02:09.000Z","date":"2018-01-04","kind":"exercise","acquired":true,"shares":1388,"price":42.22,"value":58601.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017."}],"balance_after":6352,"source":{"system":"sec-edgar","filing":"0001325812-18-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000004/edgardoc.xml","form_type":"4"}},{"id":4112703,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Restricted Stock Unit","published_at":"2018-01-03T22:26:31.000Z","date":"2017-12-30","kind":"exercise","acquired":false,"shares":8502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ALNY common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in full on December 30, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in full on December 30, 2017."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8502},"source":{"system":"sec-edgar","filing":"0001325812-18-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000002/primary_doc.xml","form_type":"4"}},{"id":4112702,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-03T22:26:31.000Z","date":"2017-12-30","kind":"tax_withholding","acquired":false,"shares":3538,"price":127.05,"value":449502.9,"ownership":{"direct":true},"balance_after":4964,"source":{"system":"sec-edgar","filing":"0001325812-18-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000002/primary_doc.xml","form_type":"4"}},{"id":4112701,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2018-01-03T22:26:31.000Z","date":"2017-12-30","kind":"exercise","acquired":true,"shares":8502,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8502,"source":{"system":"sec-edgar","filing":"0001325812-18-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000002/primary_doc.xml","form_type":"4"}},{"id":4123806,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2017-12-21T22:00:59.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":1388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee.  Effective December 20, 2017, the compensation\ncommittee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":1388,"derivative":{"exercise_price":42.22,"exercise_date":"2017-12-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":1388},"source":{"system":"sec-edgar","filing":"0001325812-17-000040","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581217000040/edgardoc.xml","form_type":"4"}},{"id":4169047,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2017-11-08T22:25:58.000Z","date":"2017-11-06","kind":"grant","acquired":true,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee.  Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":1800,"derivative":{"exercise_price":88.95,"exercise_date":"2017-11-06","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001553878-17-000066","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000066/edgardoc.xml","form_type":"4"}},{"id":4203220,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2013 (right to buy)","published_at":"2017-09-22T21:09:22.000Z","date":"2017-09-20","kind":"grant","acquired":true,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock.  One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee.  Effective September 20, 2017, the compensation committee of the company determined the second performance criteria had been met and the option will vest as to one-third of the shares."}],"balance_after":1667,"derivative":{"exercise_price":63,"exercise_date":"2017-09-20","expiration_date":"2023-12-17","underlying":"Common Stock","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0001553878-17-000052","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000052/edgardoc.xml","form_type":"4"}},{"id":4259151,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Performance Stock Option 2014 (right to buy)","published_at":"2017-07-11T20:35:06.000Z","date":"2017-07-07","kind":"grant","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares."}],"balance_after":5500,"derivative":{"exercise_price":96.45,"exercise_date":"2017-07-07","expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001553878-17-000045","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000045/edgardoc.xml","form_type":"4"}},{"id":4316081,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-17T22:45:21.000Z","date":"2017-05-16","kind":"exercise","acquired":false,"shares":5625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":18.66,"expiration_date":"2022-12-20","underlying":"Common Stock","underlying_shares":5625},"source":{"system":"sec-edgar","filing":"0001553878-17-000013","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000013/primary_doc.xml","form_type":"4"}},{"id":4316080,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-17T22:45:21.000Z","date":"2017-05-16","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.1,"expiration_date":"2021-11-30","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001553878-17-000013","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000013/primary_doc.xml","form_type":"4"}},{"id":4316079,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2017-05-17T22:45:21.000Z","date":"2017-05-16","kind":"sale","acquired":false,"shares":9375,"price":70,"value":656250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001553878-17-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000013/primary_doc.xml","form_type":"4"}},{"id":4316078,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2017-05-17T22:45:21.000Z","date":"2017-05-16","kind":"exercise","acquired":true,"shares":3750,"price":7.1,"value":26625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016."}],"balance_after":9375,"source":{"system":"sec-edgar","filing":"0001553878-17-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000013/primary_doc.xml","form_type":"4"}},{"id":4316077,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Common Stock","published_at":"2017-05-17T22:45:21.000Z","date":"2017-05-16","kind":"exercise","acquired":true,"shares":5625,"price":18.66,"value":104962.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016."}],"balance_after":5625,"source":{"system":"sec-edgar","filing":"0001553878-17-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000013/primary_doc.xml","form_type":"4"}},{"id":4508040,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Restricted Stock Units","published_at":"2017-01-03T22:33:22.000Z","date":"2016-12-30","kind":"grant","acquired":true,"shares":8502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ALNY common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in full on December 30, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in full on December 30, 2017."}],"balance_after":8502,"derivative":{"underlying":"Common Stock","underlying_shares":8502},"source":{"system":"sec-edgar","filing":"0001325812-17-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581217000002/edgardoc.xml","form_type":"4"}},{"id":4513405,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":87757,"kind":"person","name":"Mason Michael","position":1,"cik":"0001514291","reported_name":"Mason Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Treasurer"}}],"security":"Stock Option  (right to buy)","published_at":"2016-12-22T21:20:27.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":5550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award.  The reporting person also received an option to purchase 5,550 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":5550,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":5550},"source":{"system":"sec-edgar","filing":"0001325812-16-000111","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581216000111/edgardoc.xml","form_type":"4"}}]}